Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?

Semin Oncol. 2003 Apr;30(2):329-31. doi: 10.1053/sonc.2003.50055.

Abstract

Since the presence of an M-component is an essential disease feature in both multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM), the decrease in the M-protein size applied for response in MM is also a crucial criteria for assessing response in WM. However, WM frequently displays lymphoma-like features that should be included in the response criteria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Humans
  • Immunoglobulin M / blood
  • Multiple Myeloma / blood*
  • Multiple Myeloma / drug therapy*
  • Prognosis
  • Remission Induction
  • Treatment Failure
  • Treatment Outcome
  • Waldenstrom Macroglobulinemia / blood*
  • Waldenstrom Macroglobulinemia / drug therapy*

Substances

  • Antineoplastic Agents
  • Immunoglobulin M